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ABSTRACT 
Glioma stem-like cells (GSC) with tumor initiating activity orchestrate the cellular hierarchy in 
glioblastoma (GBM) and engender therapeutic resistance. Recent work has divided GSC into two 
subtypes with a mesenchymal (MES) GSC population as the more malignant subtype. In this 
study, we identify the FOXD1-ALDH1A3 signaling axis as a determinant of the MES GSC 
phenotype. The transcription factor FOXD1 is expressed predominantly in patient-derived 
cultures enriched with MES, but not with the proneural (PN) GSC subtype. shRNA-mediated 
attenuation of FOXD1 in MES GSC ablates their clonogenicity in vitro and in vivo. Mechanistically, 
FOXD1 regulates the transcriptional activity of ALDH1A3, an established functional marker for 
MES GSC. Indeed, the functional roles of FOXD1 and ALDH1A3 are likely evolutionally 
conserved, insofar as RNAi-mediated attenuation of their orthologous genes in Drosophila blocks 
formation of brain tumors engineered in that species. In clinical specimens of high-grade glioma, 
the levels of expression of both FOXD1 and ALDH1A3 are inversely correlated with patient 
prognosis. Lastly, a novel small molecule inhibitor of ALDH we developed, termed GA11, displays 
potent in vivo efficacy when administered systemically in a murine GSC-derived xenograft model 
of GBM. Collectively, our findings define a FOXD1-ALDH1A3 pathway in controlling the 
clonogenic and tumorigenic potential of MES GSC in GBM tumors. 
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Introduction 
Glioblastoma (GBM) is the most common and fatal primary brain tumor in adults. GBM tumors are 
resistant to conventional radiation therapy and chemotherapies, making the current available 
treatments ineffective (1). Intra-tumoral cellular heterogeneity in GBM contributes to tumor 
aggressiveness and therapy resistance, with glioma stem-like cells (GSCs) at the apex of the 
hierarchy (1,2). GSCs are poorly differentiated tumor cells with stem cell properties including 
self-renewal, and are responsible for tumor initiation (3-5). Recently, we and others established 
patient-derived GSC lines from GBM patients, which contain two distinct and mutually-exclusive 
GSC subtypes termed Proneural (PN) and Mesenchymal (MES) (4,6). MES GSCs, the more 
aggressive and radio-resistant subtype, express higher levels of ALDH1A3 than PN GSCs in vitro 
(6), suggesting that ALDH1A3 is a potential marker of MES GSCs. Therefore, understanding the 
regulatory pathway(s) controlling ALDH1A3 expression in this cell type would be expected to 
identify new and relevant therapeutic targets. 
The Forkhead family of transcription factors (TFs) regulate a wide variety of cellular functions 
during development and many are implicated in cancers (7,8). As a member of this family, FOXD1 
is preferentially expressed in human embryonic tissues, including kidney and testis, but not in 
adult tissues (9). Moreover, FOXD1 regulates organogenesis (10-12), especially the commitment 
to a mesenchymal lineage during organogenesis (13-15). FOXD1’s regulatory role in stemness is 
further demonstrated by facilitating the reprogramming of mouse embryonic fibroblasts into 
induced pluripotent stem cells (16). Recent studies have suggested parallels between 
reprogramming and tumorigenesis, and highlighted the shared transcription factors involved. 
Similarly, the deregulation of FOXD1 is implicated in the tumorigenesis of cancers of prostate, 
breast, and clear cell sarcoma of the kidney (17-19). Nonetheless, the physiological roles of 
FOXD1 in brain cancers and GSCs remain unknown. 
In this study, we demonstrate that FOXD1 is critical for the maintenance of MES GSCs, and 
thus, the tumorigenicity of this subtype of GBM tumors. By exploring our genome-wide expression 
 4
profiling data, we identified FOXD1 as the most up-regulated Forkhead TF in the patient-derived 
MES GSC enriched cultures. We found that FOXD1 promotes clonogenicity and tumorigenicity of 
MES GSCs both in vitro and in vivo by the direct transcriptional regulation of the key molecule 
ALDH1A3. Subsequently, we verified that the tumorigenicity of FOXD1 is mediated by ALDH1A3. 
We also proved that FOXD1 and ALDH1A3 are prognostic factors in glioma clinical samples. 
Finally, we developed novel anti-ALDH small molecule inhibitors and demonstrated effectiveness 
in vitro and in vivo.  
 
Materials and Methods 
Ethics 
This study was performed under the supervision of the respective Institutional Animal Care and 
Use Committees, and the Human Subjects Research protocols were approved by the Institutional 
Review Board at the University of Alabama at Birmingham (UAB), MD Anderson Cancer Center 
(MDA) and/or Ohio State University (OSU) as described previously (6,20).  
 
GSC cultures 
The glioma (neuro)spheres used in this study were generated at OSU and MDA. Neurosphere 
cultures from clinical samples were established and characterized as described previously 
(Supplementary Table S1) (6,20). The detailed source, year of receipt, and culture methods are 
described in Supplementary information. The unique identities of each glioma neurosphere line 
were confirmed by short tandem repeat (STR) analysis as described in Supplementary Table S2 
(20).  
 
Mouse intracranial xenograft tumor models 
The GSC suspension (1×104 cells for MES83 and 2.5×105 cells for MES267) was injected into the 
brains of nude mice (6-week-old) as previously described (20,21). When neurological symptoms 
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observed, mice were sacrificed and mouse brains were collected for analysis.  
 
Lentivirus transduction 
Two independent lentiviral shRNA constructs for knocking down FOXD1 were purchased from 
Sigma (TRCN0000013970 and TRCN0000230322). For overexpression, cDNAs of FOXD1 
(RC220504, Origene), and FOXG1 (RC207964, Origene) were subcloned into a lentiviral vector 
(Origene, PS100064) according to the manufacturer’s protocol.  Lentiviruses were packaged in 
293FT cells (from Invitrogen at 2013). The lentivirus transduction was performed as previously 
described (20). 
 
Neurosphere formation assay 
MES83 and MES28 GSCs infected with lentivirus were seeded into 96 well plates at 1, 10, 20, 30, 
40, and 50 cells per well. After 7 days for MES83 GSCs and 10 days for MES28 GSCs, the 
numbers of spheres with diameters greater than 60μm were counted. Data were analyzed as 
described previously (http://bioinf.wehi.edu.au/software/elda/) (22). 
 
Immunohistochemistry scoring 
German immunohistochemical score (GIS) was used to evaluate the expression of FOXD1 and 
ALDH1A3 (23,24). The detailed procedure is provided in the supplementary information. 
 
Western blot 
The detailed procedure is provided in the supplementary information. Original film scans of 
western blots were shown in Supplementary Fig. S1. 
 
GEO accession numbers 
The accession numbers of GEO datasets used in this study are GSE67089, GSE4290, GSE4536, 
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and GSE2223.  
 
Drosophila stock 
The following transgenic Drosophila flies were used: repoGAL4 UAS-GFP/TM3, Sb, UAS-ptenRNAi, 
UAS-RasV12/Cyo, UAS-aldhRNAi/Cyo, ptcGAL4 UAS-GFP/Cyo, UAS-fd59ARNAi, and UAS-fd59A. 
The Drosophilas for all experiments were incubated at 25°C. 
 
Immunofluorescence, imaging, and quantification in Drosophila samples 
Immunofluorescence was performed as described (25) and the images were captured using the 
Olympus Fluoview 1000 confocal microscope.  
 
Statistical analysis 
Data are presented as mean ± SD. The number of replicates for each experiment is stated in the 
figure legend. Statistical differences between and among groups were determined by two tailed 
t-test and one-way analysis of variance (ANOVA) followed by Dunnett’s post-test, respectively. 
The statistical significance of Kaplan–Meier survival plot was determined by log-rank analysis. 
Statistical analysis was performed by Microsoft Excel 2013 and Graphpad Prism 6.0, unless 
mentioned otherwise in the figure legend. P<0.05 was considered as statistically significant. 
 
Additional details about the materials and methods are available in the supplementary 
information. 
 
Results 
FOXD1 and FOXG1 exhibit inverse expression pattern in GSCs.  
To identify the TFs critical for the GSC phenotype, we explored our dataset (GSE67089 (6)) with 
30 patient-derived glioma sphere cultures and 3 human fetal brain-derived sphere cultures 
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(normal spheres) for the expression levels of all TFs (1,988 genes (26)). Twenty eight TFs were 
found up-regulated in MES glioma spheres by more than 10 fold compared to normal neural 
progenitor cells. Ten TFs were at higher levels in MES glioma spheres by more than 11 fold than 
the levels of these TFs in PN glioma spheres. Among them, seven TFs were overlapped, 
including FOSL1, FOXD1, PLAGL1, STAT6, ARNTL2, BNC1, and HTAIP2 (Fig.1A). 
Forkhead TFs are involved in deciding cell fates during development and tumorigenesis 
(7,16). Our previous study demonstrated the requirement of one Forkhead TF, FOXM1, for the 
survival and proliferation of oncogenic but not normal neural stem cells (27-29).  Therefore, we 
focused on the Forkhead TFs. FOXD1 was the most up-regulated MES-associated gene in the 
Forkhead family, whereas FOXG1 was the most up-regulated gene in PN glioma spheres (Fig. 1B 
and Supplementary Fig. S2A, B). This was validated by RT-qPCR (Fig. 1C and D) and western 
blot (Fig. 1E) with six patient-derived GSC-enriched cultures. In western blot assays, ALDH1A3, 
CD44, and AXL were included as MES markers while OLIG2 as a PN marker. Similarly, 
immunocytochemistry exhibited that glioma sphere line MES83 has a higher expression of 
nuclear FOXD1 than PN84 and PN157 (Fig. 1F). We then investigated whether the stem cell 
fraction in MES and PN glioma spheres express FOXD1 and FOXG1, respectively. Our previous 
studies identified CD133 as a PN GSC marker while ALDH1A3 as MES GSC marker (4,6,27). As 
expected, FOXD1 was almost exclusively expressed in the ALDHhigh subfraction of MES83 cells, 
but not in ALDHlow subpopulations (Fig. 1G and Supplementary Fig. S2C). In contrast, the 
CD133high subpopulation had significantly higher expression of FOXG1 than CD133low 
subpopulations in the PN157 glioma spheres (Fig. 1H and Supplementary Fig. S2D). To extend 
this observation, we performed bioinformatics analysis using another clinical data (IVY GBM Atlas 
Project database) (http://glioblastoma.alleninstitute.org/). GBM is known to display intra-tumoral 
cellular heterogeneity. We investigated RNAseq data that was collected from different regions of 
GBM tumor tissues that exhibit distinct cellular subtypes including PN and MES tumor cells. This 
analysis showed an inverse pattern of the expression levels of FOXG1 and FOXD1 in different 
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regions (Supplementary Fig. S2E and F). In contrast, there were no significant differences in 
either FOXD1 or FOXG1 among the GBM subtypes in the TCGA dataset (Supplementary Fig. 
S2G). The TCGA dataset measures the average expression levels of genes. This maybe the 
possible reason why the expression level of either FOXG1 or FOXD1 failed to show a significant 
difference among the four subtypes of GBM. Collectively, these data suggest that FOXD1 and 
FOXG1 exhibit inverse expression profiles in vitro: FOXD1 is elevated in MES, while FOXG1 is 
elevated in PN GSCs. 
 
FOXD1 expression is associated with poorer prognosis in glioma patients.  
We then examined whether FOXD1 expression is associated with the histopathological grade of 
glioma and patient prognosis. With immunohistochemistry, 44 glioma tumor tissues with varying 
grades and nine adjacent normal brain tissues were analyzed. Intense immunostaining, indicating 
FOXD1 expression, was observed in the nuclei of high-grade glioma tissues (Grade II: 2 of 4; 
Grade III: 12 of 16; Grade IV: 10 of 24) but rarely in normal brain tissues (1 of 9) (Fig. 2A and B). 
The survival periods of patients with high levels of FOXD1 were significantly shorter than those 
with FOXD1 intermediate expression (Fig. 2C, P=0.0039). Inversely, patients with low FOXD1 
expression exhibited better prognosis than those with high expression (Fig. 2C, P=0.0324). 
Consistently, GBM-derived spheres expressed higher FOXD1 than normal brain-derived spheres 
(GSE4536, Fig. 2D (30)). Similar results were obtained from two other datasets (GSE2223, Fig. 
2E (31); and GSE4290, Fig. 2F (32)), and from the Rembrandt database (Fig. 2G). The elevated 
expression of FOXD1 was also associated with poorer survival in Rembrandt database (Fig. 2H). 
Altogether, these data suggest that the expression of FOXD1 is elevated in high-grade glioma 
and is a clinically-relevant target in GBM.  
 
FOXD1 is required for the clonogenicity of MES GBM in vitro and in vivo.  
To investigate the physiological role of FOXD1 in MES GSCs, we knocked down the expression 
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of FOXD1 using two different lentiviral shRNA vectors in MES glioma sphere lines (MES83 and 
MES28) (4,6); a non-targeting shRNA (shNT) was used as a negative control.  Western blotting 
showed that both shRNA clones were capable of knocking down FOXD1, with clone #1 having 
higher efficiency (Fig. 3A). As a result, MES glioma spheres with FOXD1 knocked-down (KD) 
grew significantly slower (33) than control cells (Fig. 3B). Moreover, the sphere forming capacity 
of these cells was dramatically decreased (Fig. 3C and D). Of note, the extent to which cell growth 
and clonogenicity were inhibited was more prominent with shFOXD1#1 than shFOXD1#2, which 
was consistent with their effects on FOXD1 KD. Our previous study demonstrated that MES, not 
PN GSCs depended more on glycolysis (6). As expected, lactic acid levels as a measure of 
glycolysis were largely reduced in MES83 cells transduced with shFOXD1#1, indicating that 
FOXD1 may be involved in the regulation of glycolysis of MES GSCs (Supplementary Fig. S3). To 
determine whether FOXD1 is essential for tumorigenicity in MES glioma spheres in vivo, we used 
orthotopic xenografts into mouse brains. Injection of MES83 spheres into the striatum of 
immunocompromised mouse brains resulted in lethal tumors within 30 days (6,34). Although the 
cells transduced with the lentiviral shNT construct did not show altered tumorigenesis or 
subsequent mouse survival, xenografting of the FOXD1 silenced MES glioma spheres diminished 
the proportion of tumor formation (3 of 5 mice) and prolonged survival periods (Fig.3E). 
Histologically, the tumors in the control mice were highly vascularized GBM-like brain tumors with 
central necrosis, and developed by day 18 after transplantation (Fig. 3F and G). 
 
FOXD1 regulates ALDH1A3 transcription in MES glioma spheres.  
Because FOXD1 is almost exclusively expressed in ALDHhigh MES GBM cells, not in ALDHlow 
cells (Fig 1G), we examined whether FOXD1 transcriptionally regulates the ALDH1A3 gene, 
thereby orchestrating the stem cell properties in MES GSCs. Indeed, FOXD1 silencing in the 
MES83 glioma spheres significantly decreased the ALDH1A3 mRNA and protein levels (Fig. 4A 
and B). Since there is a common Forkhead TF binding motif in the promoter region of the 
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ALDH1A3 gene (Supplementary Fig.S4A), we hypothesized that FOXD1 activated ALDH1A3 
transcription. Thus, we performed a luciferase assay to measure ALDH1A3 promoter activity 
upon exogenous expression of FOXD1 in 293T cells and MES83 spheres (Fig. 4C and D). As 
expected, ectopically expressed FOXD1 increased ALDH1A3 reporter activity.  Since FOXD1 and 
FOXG1 exhibit mutually-exclusive expression patterns (Fig. 1B-D), we assumed that FOXG1 may 
counteract FOXD1 activity in MES GSCs. Intriguingly, co-expression of FOXG1 and FOXD1 in 
MES83 spheres counter-acted ALDH1A3 reporter activities driven by FOXD1 alone (Fig. 4C and 
D). Further, the transcriptional regulation of ALDH1A3 by FOXD1 was confirmed by chromatin 
immunoprecipitation PCR, which indicated that FOXD1 directly binds to the promoter region of 
the ALDH1A3 gene in MES28 glioma spheres (Fig. 4E). In addition, the overexpression of FOXD1 
in MES83 increased the expression of ALDH1A3 (Fig. 4F). To investigate the physiological role of 
the FOXD1-ALDH1A3 axis in MES GSCs, we evaluated whether ALDH1A3 overexpression 
rescues the phenotypes of MES glioma spheres induced by FOXD1 KD. The reduced in vitro cell 
growth and neurosphere formation by FOXD1 KD were partially, yet not completely, restored by 
the overexpression of ALDH1A3, but not by the control vector (Fig. 4G, H and Supplementary Fig. 
S4B). On the other hand, FOXD1 overexpression alone did not induce any noticeable changes in 
the PN spheres, at least in the expressions of representative markers (AXL, CD44, and Olig2) 
(Supplementary Fig. S4C). We also analyzed dataset (GSE67089) in our previous publication (6) 
for the expression levels of FOXD1 with all the members of ALDH family. We consistently found 
that FOXD1 is co-expressed with ALDH1A3, but not other ALDH members, in MES but not in PN 
subtype spheres (Supplementary Fig. S4D). Collectively, these data suggest that FOXD1 is 
required, but not sufficient, for the establishment of the MES phenotype in GSCs. 
 
FOXD1 and ALDH1A3 are evolutionarily conserved genes that contribute to glial 
neoplasms.  
Previously, we reported that ALDHhigh MES glioma sphere cells have higher clonogenic potential 
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in vitro than ALDHlow cells in MES GBM (6). To compare the in vivo tumorigenic abilities of 
ALDHhigh and ALDHlow cells in MES glioma spheres, we injected ALDHhigh or ALDHlow MES83 cells 
into mouse brains at two different cell numbers (100 and 1,000 cells). When 100 ALDHlow or 
ALDHhigh cells were injected into mouse brains, only one of six mice injected with ALDHlow cells 
died by 24th day after transplantation. In contrast, four of six mice in the ALDHhigh group died due 
to tumor burden. Similar results were observed when 1,000 tumor cells were injected (Fig. 5A), 
indicating that the tumor initiating cells reside in the minor subset of MES GBM cells with elevated 
ALDH1 activity (approximately 7% of the MES83 cells).  
Next, we examined the functional role of FOXD1 and ALDH1A3 in Drosophila. In flies, the 
orthologs of FOXD1and ALDH1A3 are fd59A (35) and DmALDH (36), respectively. fd59A is 
highly expressed in the Drosophila larval (embryonic) Central Nervous System (CNS) (35). We 
used recently established Drosophila glioma model involving co-activation of oncogenic Ras and 
PI3K pathways by the GAL4 UAS system (repoGAL4 UASPTENRNAi UASRasV12), which causes 
the formation of invasive glial neoplasms that mimic human gliomas (37). In the larval glial 
neoplasms derived from the repoGAL4 UASPTENRNAi; UASRasV12 larvae, Fd59A and ALDH 
levels were substantially upregulated compared to the normal CNS (repoGAL4 UASGFP) (Fig. 
5B and C). To investigate if the formation of the glial neoplasms in Drosophila requires ALDH, we 
transduced UASALDHRNAi into Drosophila glioma tumors. Elimination of ALDH resulted in 
reduction in glioma growth by 1.7-fold (Fig. 5D and E, P=0.008). This anti-tumor effect of ALDH 
silencing was also observed in the mosaic models of Drosophila eye cancer (Supplementary Fig. 
S5). Next, we investigated the effects of downregulation of Fd59A in these cancers. As shown in 
Fig. 5D and E, downregulation of Fd59A resulted in a reduction in glioma growth (P=0.007) with a 
concomitant downregulation of ALDH levels (Fig. 5C). Taken together, these data suggest that 
FOXD1 and ALDH1A3 are evolutionarily conserved genes that contribute to CNS tumorigenesis 
(Fig. 5F). 
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ALDH1A3 expression indicates poor prognosis of post-surgical glioma patients.  
To interrogate whether ALDH1A3 is a clinically relevant biomarker, we analyzed 40 high-grade 
glioma patient samples (Fig. 6A). The log rank test showed that the glioma patients with higher 
ALDH1A3 protein expression has a significantly shorter post-surgical survival periods compared 
to either the intermediate or low ALDH1A3 protein expression groups (Fig. 6B, P=0.0285, 
ALDH1A3high vs. ALDH1A3intermediate; and P=0.0016, ALDH1A3high vs. ALDH1A3low). Additionally, 
the data from Rembrandt database demonstrates a similar pattern (Supplementary Fig. S6). 
These data indicate the clinical significance of ALDH1A3. 
 
The novel ALDH1 inhibitor GA11 has anti-GBM effects in vitro and in vivo.  
Based on the inhibitory effects of FOXD1 silencing on the MES GSC-derived mouse brain tumors 
and of ALDH1A3 silencing on the Drosophila brain cancer model, we sought to design novel, 
clinically efficacious small molecule inhibitors selectively targeting the ALDH1 activity for GBM 
therapies. The natural product daidzin and its congeners have been reported to inhibit ALDH1 
(38). To design clinically applicable analogs with better pharmacokinetic properties (39), we 
identified the imidazo [1,2-a] pyrimidine heterocyclic core as the essential scaffold. We added two 
planar, aromatic and lipophilic areas to this scaffold in positions two and six of the nucleus, 
thereby generating the novel small molecules GA11 and GA23 (Fig. 6C and Supplementary Fig. 
S7A). The structural assessment confirmed that the replacement of glucopyranose portion of 
daidzin with an aromatic ring reduces both hydrogen bond forming potential and rotatable bonds, 
resulting in smaller molecules with a lower polar surface area and limited flexibility. This 
modification retained the core structure of daidzin essential for inhibiting ALDH1 activity, while 
establishing a drug-like profile, i.e. a more favorable prediction of the blood-brain barrier (BBB) 
penetration. Indeed, an in silico evaluation confirmed that the physical-chemical properties of 
these novel compounds were fully consistent with those required for BBB penetration 
(Supplementary Table S3) (40). In addition, the molecular weights of GA11 and GA23 (close to 
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310, the mean value of marketed CNS drugs) are significantly lower than that of daidzin. 
Moreover, the H-bonding potential of these novel compounds is commensurate to that of 
successful CNS drug candidates. Indeed, the sum of heteroatoms capable of hydrogen bonding, 
like nitrogen (N) and oxygen (O), is less than five, conferring on the molecules a high probability of 
entering the CNS. Additionally, the rotatable bond count is less than eight, and the limited 
flexibility of the molecules should promote passive permeation through BBB. Lowering both 
molecular weight and H-bonding potential have a significant effect on the polar surface area (PSA) 
of the compounds, which is a key factor in determining the extent of BBB penetration. Unlike 
daidzin, the novel compounds have PSA values lower than the stringent cut-off 60-70 Å, which 
characterizes commercial CNS drugs (40). 
To validate the inhibitory effects, we first determined the enzymatic activity of yeast ALDH 
incubated with GA11 and GA23 in an in vitro enzymatic assay (30% of the ALDH sequences in 
yeast and eukaryotes are conserved (41)). As expected, both GA11 and GA23 inhibited the ALDH 
enzymatic activity with IC50 values in the micro molar range (Fig. 6D). GA11 was more potent.  
Further, both GA11 and GA23 inhibited human ALDH1 demonstrated by a marked reduction of 
ALDHhigh cellular populations in MES83 glioma spheres treated with GA11 and GA23 (Fig. 6E). As 
a result, both GA11 and GA23 inhibited the growth of MES glioma spheres. In contrast, PN glioma 
spheres were relatively more resistant to these two compounds (Fig. 6F and Supplementary Fig. 
S7B-D). More importantly, systemic treatment of MES83 and MES267-based mouse brain tumors 
with GA11 significantly attenuated tumor growth, thereby extending the survival of tumor bearing 
mice compared to the vehicle treated counterparts (Fig. 6G, H and Supplementary Fig. S7E).  
 
Discussion 
GBMs display intra-tumoral cellular heterogeneity; within the same tumor different cell 
populations respond differently to therapies (3,42,43). GSCs are at the apex of the cellular 
hierarchy (3,42). Thus, understanding how GSCs are maintained may improve the efficacies of 
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current therapeutic strategies. Recent evidence suggests that GSCs are subclassified into two 
subtypes with MES GSCs being more therapy-resistant (4,6). Therefore, identification of MES 
GSC regulatory molecules has the potential to lead to novel and efficacious GBM therapeutics. 
Our study (Fig. 5A) is the first demonstrating that ALDH1high GBM cells are more tumorigenic in 
vivo than the ALDH1low counterparts, indicating that ALDH1 is a specific marker for MES GSCs.  
This is further supported by analyses of clinical glioma samples (Fig. 6B). To develop 
chemotherapeutics targeting MES GSC, we synthesized a novel class of imidazo [1,2-a] pyridine 
derivatives called GA11 and GA23 as ALDH1 inhibitors. These compounds were designed based 
on the conserved structural traits of the known natural occurring inhibitors including daidzin. In 
addition to fulfilling pharmacophore needs, these novel compounds possess a good 
hydrophilic-lipophilic balance, which allows for better penetration of the BBB. In principle, both 
these features make GA11, in particular, an attractive drug candidate to target GSCs in GBM 
tumors. This structural prediction was validated in a cell-free kinase assay, which proved the 
ability of GA11 to inhibit the target enzyme ALDH in yeast (Fig. 6D) and further, an in vitro 
ALDEFLUOR assay showed the substantial decline of human ALDH1 activity in GA11-treated 
MES glioma spheres (Fig. 6E). Consistently, GA11 inhibited in vitro glioma sphere proliferation 
and in vivo xenograft growth in mouse brains (Fig 6F and G, H, respectively). Further pre-clinical 
evaluation of GA11 and its analogs is currently underway for clinical development of anti-ALDH1 
therapeutics for GBM. 
Another novel set of findings in this study is that ALDH1A3 is transcriptionally regulated by 
FOXD1 (Fig. 4E). The ALDH1A3 signaling in cancers is likely evolutionally conserved based on 
the fact that ALDH1A3 silencing in vivo displayed substantial suppression of the 
genetically-engineered Drosophila brain cancers (Fig. 5D, E). Interestingly, this FOXD1-mediated 
ALDH1A3 transcriptional activation was counter-acted by another Forkhead family member, 
FOXG1 in the MES GSC-enriched cultures (Fig. 4C, D). This data is supported by the presence of 
a Forkhead TF consensus sequence in the ALDH1A3 promoter region. These data suggest that 
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MES GSCs hijack the molecular mechanism for normal development (e.g. mouse retina) to 
promote their tumor growth (44). It is not clear, however, whether these two Forkhead TFs 
compete for the DNA binding in the ALDH1A3 promoter or if FOXG1 indirectly influences FOXD1 
signaling in MES GSCs. Additionally, the restoration of ALDH1A3 by exogenous expression did 
not fully rescue the defects in MES glioma sphere growth caused by FOXD1 silencing (Fig. 4G), 
suggesting that additional undetermined oncogenic mechanisms are likely involved in MES GBM. 
Further studies are needed to fully clarify the mechanisms by which FOXD1 maintains the MES 
GSCs phenotype and thus, GBM tumorigenesis and therapy-resistance. 
In conclusion, this study describes the upregulation of ALDH1A3 and FOXD1 in clinical 
glioma samples and establishes their functional roles in the maintenance of MES GSCs, and 
therefore MES GBM tumorigenesis. Furthermore, this study provided the first evidence 
supporting the fact that elevated FOXD1 expression is a negative prognostic factor in glioma, and 
establishes a role for FOXD1 directly regulating ALDH1A3 transcription in MES GSCs. Taken 
together, the FOXD1-ALDH1A3 axis is critical for tumor initiation in MES GSCs, therefore 
providing possible new molecular targets for the treatment of GBM and other ALDH1-activated 
cancers. 
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Figure Legends 
Figure 1. FOXD1 is a key MES GSC transcription factor. 
A. Genome-wide transcriptome microarray analysis (GSE67089) shows that FOXD1 is one of 
seven upregulated transcription factors in MES gliomaspheres when compared to Neural 
Progenitors (NPs) (>10 fold) and PN glioma spheres (>11 fold). 
B. mRNA expression levels of the Forkhead TF family members in the GSE67089 dataset reveal 
that FOXD1 and FOXG1 are the highest expressed genes in MES and PN glioma spheres, 
respectively. 
C, D. RT-qPCR analyses of FOXD1 (C) (MES vs. PN, P<0.001, n=3; MES vs. mixed, P<0.001, 
n=3, one way ANOVA) and FOXG1 (D) (MES vs. PN, P=0.0025, n=3; MES vs. mixed, P=0.2537, 
n=3, one way ANOVA) mRNA in the indicated glioma spheres. 
E. Western blot analyses of ALDH1A3, FOXD1, FOXG1, CD44, AXL and Olig2 expression in the 
indicated glioma spheres. β-actin serves as a loading control. 
F. Immunocytochemistry analyses of FOXD1 in MES83, PN84, and PN157 glioma spheres. 
Hoechst is used for nuclear staining. Bar, 50μm. 
G. RT-qPCR analyses of FOXD1 mRNA in ALDHhigh and ALDHlow cells derived from MES83 
glioma spheres. (P<0.001, n=3, t-test) 
H. RT-qPCR analyses of FOXG1 mRNA in CD133high and CD133low cells derived from PN157 
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glioma spheres. (P=0.0017, n=3, t-test) 
 
Figure 2. FOXD1 expression is clinically relevant in high-grade gliomas. 
A, B. Representative immunohistochemical images (A) and analyses (B) of FOXD1 in WHO 
grade IV (Glioblastoma), grade III glioma, grade II glioma, and non-tumor brain samples. Bar, 
50μm. (Non-tumor n=9, grade II n=4, grade III n=16, grade IV n=24). 
C. Kaplan-Meier analyses evaluating the correlation between FOXD1 protein expression and 
survival of 40 high grade glioma patients (FOXD1 high vs. low, P=0.0324; FOXD1 high vs. 
intermediate, P=0.0039; FOXD1 intermediate vs. low, P=0.2896, log rank test).  
D-F. Analyses of the indicated GEO datasets show a higher expression of FOXD1 in glioma than 
in Neural Stem Cell (NSC) samples and non-tumor tissues. D. Lee dataset (GSE4536; NSCs n=3, 
GBM n=22, GSCs n=20; P<0.001, one way ANOVA, probe set 206307_s_at). E. Bredel dataset 
(GSE2223; Non-tumor n=4, GBM n=29; P<0.0001, t test, probe set 1876). F. Sun dataset 
(GSE4290, Non-tumor n=23, grade II n=45, grade III n=31, GBM n=81; P< 0.0001, one-way 
ANOVA, probe set 206307_s_at). 
G. Analysis of the Rembrandt data shows a higher FOXD1 mRNA expression in astrocytoma 
(n=148), oligodendroglioma (n=67), mixed groups (n=11), and in GBM samples (n=228) than 
non-tumor samples (n=28) (probe set 206307_s_at). 
H. Analysis of the Rembrandt database indicates the inverse correlation between FOXD1 mRNA 
expression and post-surgical survival of glioma patients (P=0.0171, FOXD1 Up-Regulated > 
1.3-Fold, n=29 vs. FOXD1 Down-Regulated < -1.3-Fold, n=42; P=0.0243, Down-Regulated < 
-1.3-Fold, n=42 vs. Intermediate n=470, probe set: 206307_s_at). 
 
Figure 3. FOXD1 regulates MES GSC growth both in vitro and in vivo. 
A. Western blot analyses of MES83 and MES28 glioma spheres transduced with shRNA targeting 
FOXD1 (shFOXD1#1 or shFOXD1#2) or a non-targeting control (shNT). 
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B. In vitro growth assay shows that shRNAs targeting FOXD1 (shFOXD1#1 and shFOXD1#2) 
inhibit cell proliferation of MES83 and MES28 glioma spheres (P<0.0001, n=6, one-way ANOVA). 
C. Representative images of MES83 and MES28 glioma spheres transduced with shRNA 
targeting FOXD1. shNT serves as a control. Bar, 60μm. 
D. In vitro clonogenicity assays (limiting dilution neurosphere formation assays) indicate that 
FOXD1 shRNA decreases clonogenicity of MES83 and MES28 cells (MES83 P<0.001, and 
MES28 P<0.001, ELDA analyses). 
E. Kaplan-Meier analysis of nude mice harboring intracranial tumors derived from MES83 GSCs 
transduced with shNT (n=6) or shFOXD1#1 (n=5). (P=0.0014, with log-rank test) 
F, G. Representative images of brains (F) and H&E stained brain sections (G) of mice after 
intracranial transplantation of MES83 glioma spheres transduced with shNT or shFOXD1#1. Bar, 
1 mm (G, upper panel) and 100 μm (G, lower panel).  
 
Figure 4. ALDH1A3 is a functional MES GSC marker and is transcriptionally regulated by 
FOXD1.  
A. RT-qPCR analyses of ALDH1A3 and FOXD1 mRNA in MES83 glioma spheres transduced 
with shFOXD1#1 or shNT (P<0.001, n=3, with t-test). 
B. Western blot analyses of ALDH1A3 in MES83 and MES28 glioma spheres transduced with 
shFOXD1#1, shFOXD1#2 or shNT.  β-actin serves as a loading control. 
C, D. Luciferase assays with 293T cells (C) and MES83 glioma spheres (D) co-transfected with 
an ALDH1A3 promoter reporter plasmid together with overexpression vectors for the indicated 
genes (n=3). 
E. ChIP-qPCR assay using Myc antibody or control IgG in MES28 glioma spheres transfected 
with a FOXD1 (Myc-DDK-tagged) plasmid shows the binding of FOXD1 on the ALDH1A3 
promoter (P<0.001, n=3, t-test). 
F. Western blot analyses of the indicated proteins in MES83 glioma spheres transduced with the 
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overexpression plasmids encoding FOXD1, FOXG1, or empty vector. 
G, H. ALDH1A3 overexpression partially restores the in vitro proliferation (G, P<0.001, one way 
ANOVA) and neurosphere formation capacities (H, P<0.001, ELDA analysis) which are inhibited 
by shFOXD1#1 or #2 in MES83 glioma spheres. 
 
Figure 5. RNA interference-mediated silencing of FD59A and ALDH attenuates growth of 
Drosophila glial neoplasia. 
A. Upper panel, ALDEFLUOR assay in MES83 glioma spheres with or without ALDH1 inhibitor 
DEAB. Lower panel, frequencies of tumor formation of ALDH1high and ALDH1low cell populations 
of MES83 glioma spheres in mice. 
B. Expression of Fd59A (Drosophila ortholog of FOXD1) (red, grey) in the Drosophila CNS 
derived from larvae of repoGAL4 UASGFP and repoGAL4 UASGFP UASPTENRNAi UASRasv12. 
Glial cells are marked by GFP (green).  
C. Expression levels of ALDH (red, grey) in the larval CNS of repoGAL4 UASGFP (Wild type), 
repoGAL4 UASGFP UASPTENRNAi, repoGAL4 UASGFP UASRasv12, repoGAL4 UASGFP 
UASPTENRNAi UASRasv12 and repoGAL4 UASGFP UASPTENRNAi UASRasv12 fd59ARNAi. 
D. The effects of ALDHRNAi and fd59ARNAi on the growth of glial neoplasms of repoGAL4 
UASPTENRNAi UASRasv12 larvae. Both RepoGAL4 UASGFP (Wild-type) and repoGAL4 
UASPTENRNAi UASRasv12 samples are included for comparison.  
E. The quantification of brain tumor volume (brain lobe size in pixels) from the indicated larvae 
(repoGAL4 UASPTENRNAi UASRasv12 ALDHRNAi vs. repoGAL4 UASPTENRNAi UASRasv12, 
P=0.008, n=3, one way ANOVA; repoGAL4 UASPTENRNAi UASRasv12 fd59ARNAi vs. repoGAL4 
UASPTENRNAi UASRasv12, P=0.007, n=3, one way ANOVA). 
F. The schematic diagram depicts that ALDH and fd59A (dFOXD1) are evolutionarily conserved 
genes contributing tumorigenesis of glial neoplasms. 
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Figure 6. The novel ALDH small molecule inhibitor GA11 attenuates MES GSC growth both 
in vitro and in vivo. 
A. Representative immunofluroescence images of ALDH1A3 in 40 high grade glioma samples.  
DAPI is used for nuclear labeling. Bar, 50 μm. 
B. Kaplan-Meier analysis of ALDH1A3 expression indicates the negative correlation between 
ALDH1A3 protein expression and survival in high grade glioma patients. (ALDH1A3 high vs. 
ALDH1A3 intermediate, P=0.0285, ALDH1A3 high vs. ALDH1A3 low, P=0.0016, and ALDH1A3 
intermediate vs. ALDH1A3 low, P=0.1769, with log rank test). 
C. The comparison of the essential core structure of the naturally occurring ALDH inhibitor, 
daidzin, and the structures of synthesized novel imidazo [1,2-a] pyrimidine ALDH inhibitors, GA11 
and GA23. 
D. Log-dose response analysis of GA11 (upper panel) and GA23 (lower panel) in yeast. 
E. Flow cytometry analyses using ALDEFLUOR indicate that both GA11 and GA23 (5μM, 30 min) 
inhibit ALDH activity in MES83 glioma spheres. 
F. Log-dose response analyses of the effects of GA11 on the viabilities of MES83, MES267, 
PN157, PN711, glioma spheres and NHA cells. 
G, H. Treatment with GA11 (intraperitoneal injection, 20mg/kg for 7 days from day seven) 
prolongs survival periods of mice bearing MES83-derived intracranial tumors (G) (P=0.0096, with 
log rank test) and those of mice with MES267-derived intracranial tumors (H) (P=0.0262, with log 
rank test). 
 






